BioTrinity 2025: With a novel E3 ubiquitin ligase (TRIM21) for protein degradation, Cambridge, UK based TRIMTECH Therapeutics recently raised a $31 million seed round
CEO Nicki Thompson describes why she believes the company is differentied in the field, and how TRIMTECH's construct is designed to selectively degrade aggregates that cause neurodegeneration.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.